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Abstract
Background—Genome-wide association studies (GWAS) have identified determinants of
chronic obstructive pulmonary disease, asthma and lung function level, however none addressed
decline in lung function.
Aim—We conducted the first GWAS on age-related decline in forced expiratory volume in the
first second (FEV1) and in its ratio to forced vital capacity (FVC) stratified a priori by asthma
status.
Methods—Discovery cohorts included adults of European ancestry (1441 asthmatics, 2677 non-
asthmatics; Epidemiological Study on the Genetics and Environment of Asthma (EGEA); Swiss
Cohort Study on Air Pollution And Lung And Heart Disease In Adults (SAPALDIA); European
Community Respiratory Health Survey (ECRHS)). The associations of FEV1 and FEV1/FVC
decline with 2.5 million single nucleotide polymorphisms (SNPs) were estimated. Thirty loci were
followed-up by in silico replication (1160 asthmatics, 10858 non-asthmatics: Atherosclerosis Risk
in Communities (ARIC); Framingham Heart Study (FHS); British 1958 Birth Cohort (B58C);
Dutch asthma study).
Results—Main signals identified differed between asthmatics and non-asthmatics. None of the
SNPs reached genome-wide significance. The association between the height related gene DLEU7
and FEV1 decline suggested for non-asthmatics in the discovery phase was replicated (discovery
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P=4.8×10−6; replication P=0.03) and additional sensitivity analyses point to a relation to growth.
The top ranking signal, TUSC3, associated with FEV1/FVC decline in asthmatics (P=5.3×10−8)
did not replicate. SNPs previously associated with cross-sectional lung function were not
prominently associated with decline.
Conclusions—Genetic heterogeneity of lung function may be extensive. Our results suggest
that genetic determinants of longitudinal and cross-sectional lung function differ and vary by
asthma status.
Keywords
Asthma; cohort studies; genome-wide association; lung function decline; heterogeneity
INTRODUCTION
Low lung function is a feature of both asthma and chronic obstructive pulmonary disease
(COPD), with twin studies demonstrating strong heritability (0.51 to 0.77) for forced
expiratory volume in the first second (FEV1)1, 2. The two respiratory diseases and lung
function itself share predisposing and phenotypic features, including increased airway
responsiveness and atopy as well as exogenous risk factors3, 4. Genome-wide association
studies (GWAS) have identified novel genetic loci for asthma5–10, COPD11–14, and lung
function15–18 and provide the opportunity to study agnostically their overlap in genetic
background19. Some of the implicated genes, such as PDE4D, support a link between
asthma and COPD which may be rooted in shared pathways during lung development20.
However, the majority of the genes implicated in asthma or COPD GWAS analyses have not
been identified as top association signals in GWAS for lung function in the general
population15–18, with the exception of HHIP and FAM13A being associated with both lung
function15–18 and COPD11–14. Several lines of evidence suggest that different genes
influence lung function in asthmatics and in non-asthmatics. Genome-scans in family based
linkage studies identified some, but overall limited overlap between chromosomal regions
linked to lung function in asthmatics21, COPD patients22 and in the general population23 and
it has been suggested that genetic variation may be more important for lung function in
asthma after adjusting for smoking and body size differences21, 24, 25.
Here, we present results from the first lung function GWAS conducted separately for
asthmatics and non-asthmatics. This current study also focuses on the rate of lung function
decline in adults instead of cross-sectional lung function parameters tested in previous
GWAS15–18. The discovery cohorts included two population-based studies (SAPALDIA and
ECRHS) and one asthma family-based study (EGEA), all of European ancestry with highly
comparable and standardized assessment of respiratory health parameters including
spirometry from two time points ten years apart. These three studies had been included in
the GWAS for asthma conducted by the GABRIEL consortium7. Replication cohorts
included three population-based cohorts (FHS, ARIC, B58C) and one family-based asthma
study (the Dutch Asthma Study).
METHODS
Discovery cohorts and study population
Three large multi-centric cohorts EGEA26, SAPALDIA27 and ECRHS28 constitute the ESE-
consortium. Personal factors of relevance to lung function decline were assessed by
interview and anthropometric measurements at baseline and follow-up. Participants included
in discovery phase were derived from the nested asthma case/control samples (SAPALDIA
and ECRHS) or from the entire study population (EGEA) subjected to genome-wide
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genotyping in the context of the GABRIEL asthma GWAS7. Baseline and follow-up
examination were roughly 10 years apart. The analysis was restricted to adult participants
(age ≥18 years at the time of the baseline spirometry) with complete information on age,
height and sex as well as valid lung function measure from both surveys. Cohort study
protocols were in agreement with the Declaration of Helsinki and obtained ethical approval
from their respective regional and/or national review boards.
Lung function assessments, asthma status and genotypes
At each visit, a minimum of two acceptable forced expiratory flows, forced vital capacity
(FVC) and forced expiratory volume in the first second (FEV1) complying with American
Thoracic Society criteria were obtained26–29. No bronchodilator was administered. Based on
questionnaire data, asthmatics were defined as asthma self-report at any of the completed
surveys and family-based studies considered additional clinical asthma criteria (see online
repository). Genotyping for discovery cohorts was centrally performed on the Illumina
Human 610quad BeadChip at the Centre National de Génotypage (CNG, Evry, France)7.
Imputation of genotypes based on Hapmap2 reference panel, investigation of population
stratification and quality control criteria are described in Figure EI and Table EI in the
Online Repository.
Replication Cohorts
Four cohorts of European ancestry with available genome-wide data, ARIC30, FHS15;
B58C31; Dutch asthma study32 were used for replication. Subjects included in the current
analysis were older than 24 years, had complete information on covariates (age, height, and
sex) and valid lung function measures from at least two time-points. The lung function
measurements were conducted at least ten years apart, except three years apart for ARIC
(Table I). Distinct genotype data platforms and imputation software were used (Table EII,
Online Repository).
Statistical analysis
Annual decline in FEV1 and FEV1/FVC was calculated as difference between follow-up
and baseline spirometric measurements (mL for FEV1 and % for FEV1/FVC) divided by the
duration of follow-up in years. Standardized residuals were derived from sex-specific linear
regression models adjusted for age, height and study centre in asthmatics and non-asthmatics
separately. Comparability between studies of standardized residuals was tested using
Wilcoxon-Mann-Whitney test (P>0.94). The standardized residuals were used as dependent
variable and regressed on genome-wide single nucleotide polymorphisms (SNPs) adjusted
for study-specific principal components capturing population ancestry (see online
supplement for details). Study-specific SNP effect estimates were combined through meta-
analysis using fixed and random effects models. We used a threshold of P<5×10−8 (the
Bonferroni adjustment for one million independent tests) to declare a pooled effect as
genome-wide significant. Selection criteria for replication loci are described in the methods
section of the online repository. SNPs with suggestive evidence of association with decline
in FEV1 or FEV1/FVC were chosen for in silico replication (Table EIII, Online Repository).
Study-specific regression models and meta-analyses across replication cohorts were as
described for the discovery phase. Replication cohorts with spirometry data from more than
two different time points modelled the lung function decline phenotype by fitting a least-
squares slope using the available data (FHS, Dutch asthma study). P≤0.05 was considered as
statistically significant at the replication level.
The results of the main meta-analyses for the top 1000 SNPs are available in the online
repository (Table EIV A to D, Online Repository). We also conducted a meta-analysis by
combining non-asthmatic and asthmatic samples and tested for heterogeneity between these
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samples (Table EV, Online Repository). Additional sensitivity analyses were done by: a)
restricting the GWAS sample to subjects aged 30 and older for FEV1 decline (Table EIV E
and F, Online Repository); b) conducting GWAS analyses on percent change instead of
absolute annual decline in lung function (Table EIV G to J, Online Repository); c)
investigating smoking stratified joint effects for replications SNPs (Table EVI, Online
Repository); d) excluding ARIC, a cohort having substantially shorter follow-up time that
the other cohorts (three years instead of ten years) from replication analyses (Table EVII,
Online Repository). Methods and results of these additional analyses are described in the
online repository.
RESULTS
Characteristics of the study populations
The cohorts included in this study differed by age and type of recruitment, and accordingly
in lung function and the proportion of subjects with FEV1/FVC below 70% (Table I, Table
EVIII, Online Repository). Baseline lung function parameters, but not their annual changes
were lower in asthmatics when compared to non-asthmatics in each study. The proportion of
never smokers was comparable among asthmatics, but varied among non-asthmatics
(ranging from 28.5% in B58C to 46.5% in EGEA). No substantial differences in the
smoking prevalence between people with and without asthma were observed within each
study. Comparing the discovery cohorts in more detail (Table EVIII, Online Repository),
atopy (total IgE ≥100kU/ml) and hay fever were more prevalent in both asthmatics and non-
asthmatics from EGEA when compared to ECRHS and SAPALDIA. Current asthma was
more prevalent (84.4%) in EGEA than in SAPALDIA (25.5%) or ECRHS (43.3%) and the
prevalence of a positive family history for asthma was also highest in EGEA, in agreement
with the study design. Asthmatics from EGEA had a younger age of disease onset due to the
mode of recruitment of the proband.
Main findings from meta-analyses of discovery and replication phase
In the discovery phase, GWAS meta-analysis of decline in FEV1 and FEV1/FVC was
conducted in 2677 non-asthmatics and in 1441 asthmatics. Genomic inflation factors were
low for both lung function parameters (λ<1.047, Table EIX, Online Repository) suggesting
minimal unaccounted population stratification. The replication panel included a total of
10’858 non-asthmatics and 1’138 asthmatics. Thirty lead SNPs belonging to 30 loci
(5×10−8< Pdiscovery <6×10−5) were chosen for replication.
The four lung function parameter- and asthma-specific meta-analyses identified one
association signal that almost reached the genome-wide significance level (P = 5.3×10−8) at
the locus 8p22 containing the TUSC3 gene for FEV1/FVC decline in asthmatics while all
other signals had P<5×10−7 (Figure I), but this signal was not associated with FEV1/FVC
decline in asthmatics in the replication sample. The only locus of the selected replication
candidate loci that formally replicated was 13q14.3, containing the DLEU7 gene, associated
with decline in FEV1 in the non-asthmatics (Pdiscovery=4.8×10−6 and Preplication=0.03).
In the global post hoc analysis combining both asthmatics and non-asthmatics (N=4118), a
striking finding was the absence of any pronounced association signals (P >1×10−6) despite
increased statistical power. This was in agreement with the minimal overlap of association
signals observed in asthmatics and non-asthmatics separately. Most signals at P<10−5 from
the asthma-stratified analysis in the discovery phase exhibited statistically significant
heterogeneity of effects between the two groups (Table II). At the replication stage, none of
the replication SNPs was associated with lung function decline in asthmatics and non-
asthmatics combined.
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Association signals for annual decline in FEV1 in non-asthmatics
Of fifteen SNPs associated at P<10−5 with decline in FEV1 in non-asthmatics ten were
clustered at position 112.3 Mb on chromosome 9, containing genes TXN, MUSK and
SVEP1. Two of the 15 SNPs were located at 13q14.3 in a locus containing the DLEU7
gene; three SNPs belonged to three distinct loci. The association of lead and proxy SNPs in
DLEU7 (Figure II), but not TXN/MUSK/SVEP1 (Figure EII) or the other SNPs (Table II)
replicated. The G-allele of SNP rs9316500 near the DLEU7 gene was positively associated
with annual FEV1 decline in the discovery cohorts (P=4.8×10−6) and in the replication
cohorts (P=0.026). Although heterogeneity between studies was not significant (P=0.61), the
combined P value did not reach the genome-wide level (P=5.7×10−5).
Association signals for annual decline in FEV1 in asthmatics
Eighteen SNPs in nine distinct chromosomal locations were associated with decline in FEV1
in asthmatics at P<10−5. None of the loci selected for in silico replication was confirmed
(Table II).
Association signals for annual decline in FEV1/FVC in non-asthmatics
Seven loci showed association with FEV1/FVC decline in non-asthmatics at 10−6<P<10−5,
but no locus selected for replication was confirmed (Table II).
Association signals for annual decline in FEV1/FVC in asthmatics
Twelve SNPs at the locus 8p22 containing the gene TUSC3 at 15.68Mb were associated
with FEV1/FVC decline at P<10−7 in asthmatics (Figure I). Regional locus plot and forest
plot are presented in the online repository (Figure EIII). The top association signals in this
locus were conferred by distinct SNPs in each cohort, though apparently they were located
in the same putative haplotype segment in SAPALDIA and in EGEA (Figure EIV, Online
Repository). There was no statistically significant association in ECRHS. Meta-analysis of
the discovery samples identified SNP rs4831760 as top signal in TUSC3 gene, but
heterogeneity between discovery studies was borderline significant (P=0.07). The C-allele
(P=5.3×10−8) was positively associated with annual decline in FEV1/FVC in asthmatics
(Beta=0.22 ±0.04 (standard error); Table II). However this association was not replicated
(P=0.80). In the meta-analysis combining discovery and replication samples the resulting P-
value for rs4831760 was 2.8×10−5. All but the Dutch asthma study, exhibited effect
estimates in the same direction as the discovery panel. Two other candidate loci (MPP7 and
SYNE2) also failed replication testing.
SNPs previously associated in GWAS meta-analyses on cross-sectional lung function
The associations of top hit SNPs from previous GWAS meta-analyses on cross-sectional
lung function11, 15–18 and a replication study in asthmatics33 were assessed separately for
asthmatics and non-asthmatics in the discovery cohorts. Associations were assessed for both,
lung function parameters of decline (annual decline and percent change) and cross-sectional
lung function level. Overall, a subset of variants and loci showed replication of association
with cross-sectional lung function in either non-asthmatics or asthmatics. Few of the loci
showed strong association with decline in lung function. We present associations at P<0.05
in Table III and those at P≥0.05 in Table EX in the online repository.
For baseline FEV1, we observed associations for SNPs belonging to 4q24 (GSTCD,
rs11731417, P=1.3×10−4) and 15q23 (THSD4, rs1913768, P=0.003). Associations with
baseline FEV1 were mainly restricted to non-asthmatics. For baseline FEV1/FVC,
associations of SNPs of THSD4 were prominent (e.g. rs12899618, P=3.3×10−4) and again
restricted to non-asthmatics.
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For decline phenotypes of FEV1, we observed associations for SNPs in regions 6p21
(DAAM2, 0.003<P<0.02) and 4q28 (HHIP, 0.02<P<0.05) among asthmatics and in THSD4
(0.003<P<0.04) among non-asthmatics. The strongest associations observed for decline
phenotypes of FEV1/FVC were two SNPs in MMP15 (16q13, 0.003<P<0.002) in non-
asthmatics, only. Association in the combined sample of asthmatics and non-asthmatics did
not substantially alter the results.
Summary of findings from sensitivity analyses
We observed in non-asthmatics, aged 30 years and more, that MUSK and DLEU7 were no
longer prominently associated with FEV1 decline, but SNPs in other genes remained
strongly associated (ZIC1, rs6785065, P=2.3×10−5; UBL3, rs278037, P=4.8×10−5). Results
of the GWAS on percent change in lung function showed that the FEV1 association signal
for DLEU7 in the non-asthmatics was no longer significant; however the signals for MUSK
(rs1889321, P=2.92×10−7) and other loci remained unaltered (ZIC1, rs6785065,
P=2.0×10−5; KIRREL3, rs11604082, P=4.1×10−6; KIAA2117, rs10082549, P=2.7×10−6).
Top signals associated with decline in FEV1/FVC in asthmatics remained unaltered for
TUSC3 (rs4831760, P=5.2×10−8) and for SYNE2 (rs7144584, P=6.4×10−7) after taking
baseline lung function into account.
Smoking stratified analyses of the replication SNPs revealed no substantial difference in
association between ever and never smokers except for a few SNPs belonging to loci
containing SYNE2, RORA, BCAS1, or PLXNA4 genes.
Replication meta-analysis excluding the ARIC data substantially reduced sample size in
non-asthmatics and the association of DLEU7 with decline of FEV1 was no longer
significant. Instead two loci for association with decline in FEV1 in asthmatics (PLXNA4,
rs10808265, Pdiscovery=1.7×10−6, Preplication=0.02 and SLC45A3, rs16856186,
Pdiscovery=8.9×10−6, Preplication=0.04) and one locus, FLJ25393, for decline in FEV1/FVC in
non-asthmatics (rs2658782, Pdiscovery=4.3×10−6, Preplication=0.03) gained statistical
significance.
DISCUSSION
A main result of this study is the observed genetic heterogeneity of lung function decline
between asthmatics and non-asthmatics. When we combined the two groups in the discovery
phase we observed no genome-wide significant association signal despite larger sample size.
All top hit association signals detected by the asthma stratified analysis showed significant
heterogeneity according to the disease status. In the replication phase, this heterogeneity was
also confirmed for the DLEU7 locus which was associated with FEV1 decline in non-
asthmatics only. Finally, many of the SNPs identified by previous GWAS on lung function
exhibited associations specific to asthma status.
The finding of genetic heterogeneity in lung function reported here is consistent with
available evidence. Differences in familial segregation of FEV1 in asthmatic and non-
asthmatic families previously suggested genetic heterogeneity between these two groups24.
Agnostic studies investigating genetic determinants of lung function in both, family-
based 21, 22, 34–37 and population-based samples15–18, 23, 25 produced little overlap in
chromosomal regions. Genome-wide scans on lung function in asthma21, 38 or COPD22
families also suggested a heterogeneous genetic architecture of lung function.
Nevertheless, some previously reported overlapping linkage regions for the ratio of FEV1
over vital capacity (FEV1/VC) and FEV1 over the forced vital capacity (FEV1/FVC) in
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families with asthma and COPD21, 22 suggest that at least some gene(s) could be important
in the development of airway obstruction in both diseases.
Furthermore, genetic polymorphisms in glutathione S-transferases39–42 as well as
ADAM-3343–46 were associated with lower lung function at all ages and in different
subgroups of the population (general population, patients with COPD and asthma). Gene-
lung function associations that are of relevance to several population and patient strata may
be determined specifically by complex gene-gene and gene-environment interactions, as
suggested for lung function decline and its complex association with estrogen receptor 1
polymorphisms, smoking, steroid use, and gender32, 47. While ignored in ours as well as
previous GWAS, such effect modifications should be considered in the future48.
Results from the Busselton Health Study on familial aggregation and heritability of adult
lung function previously suggested the existence of genetic determinants of adult lung
function independent of asthma, atopy, cigarette smoking, height, age or sex25. Consistent
with these results, neither asthma, atopy and COPD genes previously identified in large
GWAS5–9, 11 nor genes related to smoking behavior49 were associated with lung function
decline in our study. The association of FEV1 decline with a gene related to height, DLEU7,
was ranking high, but only in subjects without asthma (rs9316500, Pdiscovery=4.8× 10−6;
Preplication=0.03). DLEU7 gene product and expression remain poorly characterized, but its
mRNA has been detected in the lung. The DLEU7 locus was identified as a determinant of
adult height in previous GWAS meta-analyses50–52. Three other height genes, HHIP,
GPR126 and PTCH, were associated with cross-sectional lung function15–17. All of these
lung function models including ours were adjusted for adult height. The observed
association, related to both HHIP and DLEU7 being associated with peak height velocity in
infancy51, suggests that aspects beyond adult height influence lung function and possibly its
response to non-genetic determinants. Several genes implicated in respiratory diseases
indicate that early lung development impacts respiratory health later in life20. Sensitivity
analyses are supportive for a growth-specific role of DLEU7. The association of genetic
variants in DLEU7 with decline in FEV1 disappeared in analyses considering baseline lung
function or restricted to subjects above age 30 with no remaining physiologic lung growth.
There might be a link between physiologic growth and unregulated cell differentiation as the
DLEU7 gene is also a proposed tumor suppressor gene in chronic lymphocytic
leukemia53–55. Evidence emerges for a role of DLEU7 in counterbalancing the proliferative
impact of NF-kB on various cell types56. The potential role of the gene product of TUSC3, a
proposed tumor suppressor gene57, in lung physiology is discussed in the Online Repository.
None of the SNPs identified in GWAS of cross-sectional lung function15–18 ranked high in
this current GWAS on lung function decline. A strong risk factor for accelerated lung
function decline in adulthood is cigarette smoking, but our study was too small to assess
gene smoking interaction at the GWAS level. We had decided a priori against smoking
adjustment as it is not a confounder, and any link between genotype and smoking is likely to
be, at least in part, in the same causal pathway (e.g. gene products metabolizing tobacco
constituents or influencing smoking behavior). Their identification as determinants of lung
function decline is of public health importance. Consistent with previous GWAS on cross-
sectional lung function15–18, neither the TUSC3 (heterogeneity between ever/never smokers
P=0.98) nor other top hit signals were modified by smoking except for SNPs in SYNE2,
RORA, BCAS1 and PLXN4. Arguments for biologic plausibility are mentioned in the
Online Repository.
The strength of the present study is the longitudinal design of all cohorts included. Repeated
spirometric assessments within the same subject is thought to capture more precisely
exogenous factors and genes leading to accelerated loss of lung function in adulthood58. The
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discovery cohorts shared comparable questionnaire and spirometry protocols and they were
specifically designed to investigate environmental and genetic causes of lung function
decline and asthma in a standardized way. Each study has two measures of pre-
bronchodilator lung function about ten years apart, but clearly our findings would be more
robust if further lung function measures were available over an even longer period of
follow-up. All discovery cohorts have used the same genotyping platform and stringent
quality control criteria have been applied.
Sample size is a limitation of this study, and remains a general challenge in lung function
studies with a need for high phenotypic comparability as spirometry results are sensitive to
technicians and devices used59. The pre-bronchodilation lung function measurements in our
and previous lung function GWAS do not allow to differentiate reversible from non-
reversible obstruction to airflow. Populations included in this study differed by age which is
also reflected by the diverging proportion of subjects with FEV1/FVC <0.7 at follow-up
between the discovery cohorts. Discovery and replication populations also differ by time
spacing between the spirometry assessments. We can only speculate of on the overall impact
of such differences. We do note that replication results were sensitive to the exclusion of
ARIC data (the study with highest mean age, largest annual decline, and shortest follow-up
time).
Other limitations are shared with any GWAS meta-analyses investigating complex
phenotypes such as lack in power for investigating gene-environment interactions or
studying subgroups of diseases. As the sample size of our study was comparatively small,
especially for the asthmatic sample in the replication phase, we had limited ability to address
differences in asthma sub-phenotypes or the impact of asthma medication intake. It is also
likely that a substantial part of complex disease may be explained by rare mutations not
considered by current GWAS. Finally, assessing the joint effect of SNPs having small
effects individually and potentially interacting with each other remains another challenge.
In conclusion, this first GWAS meta-analysis on lung function decline provides suggestive
evidence for genetic heterogeneity between persons with and without asthma and between
cross-sectionally and longitudinally measured lung function. Consistent with cross-sectional
GWAS, our results are also suggestive of height related genes playing a role. Further studies
in this area would be enhanced by greater comparability of age range, spacing of lung
function assessments, and asthma sub-phenotypes (including treatment) to decrease
phenotypic heterogeneity and therefore increase statistical power to detect true association
candidate loci60.
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• Knowledge regarding genes with pleiotropic effects on asthma, chronic
obstructive pulmonary disease as well as on lung function level and its
longitudinal course is limited.
• This first GWAS meta-analysis on lung function decline conducted separately in
non-asthmatic and asthmatic cohort participants suggests that genetic
determinants of lung function decline are different in the two groups.
• The results further suggest that previously identified genetic determinants of
cross-sectional lung function are not major determinants of the decline.
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Manhattan plots of association results for decline in lung function. A) FEV1 decline in non-
asthmatics. B) FEV1 decline in asthmatics. C) FEV1/FVC decline in non-asthmatics. D)
FEV1/FVC decline in asthmatics.
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Association of the DLEU7 locus with decline in FEV1 in non-asthmatics. A) Regional
association plot, discovery phase. B) Forest plot for rs9316500. A: Chromosome position
(NCBI build 36.3) and recombination rate (hg18 build). The sentinel SNP is represented as a
diamond and r2 for SNPs to the sentinel SNP (HapMap CEU phase II). B: The size of the
square of each study reflects the contributing weight to the meta-analysis, details in Table
EXI.
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